Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cystamine is a low-molecular-weight thiol and the oxidized disulfide form of cysteamine. It has been studied primarily as an experimental agent, in part for its ability to inhibit transglutaminase enzymes and modulate redox status. Cystamine can also increase intracellular levels of cysteine and has demonstrated neuroprotective properties in various preclinical models, including models of neurodegenerative diseases such as Huntington's disease and Parkinson's disease. The principal mechanism involves modulation of cysteine metabolism and inhibition of transglutaminase. Cystamine itself is not approved as a pharmaceutical drug for any indication, but its reduced form (cysteamine) is approved and widely used, especially in nephropathic cystinosis[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cystamine.